MedTrace Logo

Is Serum YKL-40 Capable of Predicting Intrauterine Growth Restriction (IUGR) and Preeclampsia?

NCT00836524 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2011-10-28

No results posted yet for this study

Summary

Objective: To investigate the role of maternal serum YKL-40 and uterine artery doppler, at gestational age 12, 20, 25 and 32 weeks, and the relation to preeclampsia and intrauterine growth restriction. The serum marker YKL-40 is related to conditions involving inflammation, infection, tissue remodeling, fibrosis and cancer. IUGR and preeclampsia are known to be related to inflammation and tissue remodeling.

Methods: women attending screening for downs syndrome is scanned with uterine artery doppler and delivered blood samples at GA 12, 20, 25 and 32 respectively. When pregnancy outcome is registered by medical records blood samples are retrieved and analyzed for serum YKL-40. Serum YKL-40 are correlated to the presence of bilateral notching, preeclampsia and different degrees of intrauterine growth restriction.

Conditions

Interventions

PROCEDURE

ultrasound

4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well

Sponsors & Collaborators

  • Region Zealand

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Estrid Høgdall, PhD leader · Dept of Pathology Herlev Hospital, Denmark

  • Julia S. Johansen, Dr med prof · Dept. of oncology and medicine, Herlev Hospital, Denmark

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-11-30
Completion
2012-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00836524 on ClinicalTrials.gov